Intelligence Feed event · Policy · 2026-09-12

    FDA approves Scholar Rock's Isembyld as first muscle-targeted therapy for SMA

    Question

    FDA approves Scholar Rock's Isembyld as first muscle-targeted therapy for SMA

    Direct answer

    The FDA granted commercial marketing approval for Isembyld (apitegromab-mstn), marking the first regulatory clearance for a muscle-directed SMA therapy. The treatment is indicated for use in combination with existing SMN upregulators. The approval follows positive Phase 3 SAPPHIRE study readouts showing statistically significant and clinically meaningful improvements in motor function scores across SMA patient cohorts.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-12
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “FDA approves Scholar Rock's Isembyld as first muscle-targeted therapy for SMA”, revision 1, evidence through 2026-09-12. https://marketontology.com/market-events/2026-09-12/fda-approves-scholar-rock-s-isembyld-as-first-muscle-targeted-therapy-for-sma-9c71c1

    POLICY
    FDA approves Scholar Rock's Isembyld as first muscle-targeted therapy for SMA
    The FDA granted commercial marketing approval for Isembyld (apitegromab-mstn), marking the first regulatory clearance for a muscle-directed SMA therapy. The treatment is indicated for use in combination with existing SMN upregulators. The approval follows positive Phase 3 SAPPHIRE study readouts showing statistically significant and clinically meaningful improvements in motor function scores across SMA patient cohorts.
    SRRK
    Impact
    79
    SEP 12
    SIG
    94%
    SRRK
    FDA approves Scholar Rock's Isembyld as first muscle-targeted therapy for SMA
    The FDA granted commercial marketing approval for Isembyld (apitegromab-mstn), marking the first regulatory clearance for a muscle-directed SMA therapy. The treatment is indicated for use in combination with existing SMN upregulators. The approval follows positive Phase 3 SAPPHIRE study readouts showing statistically significant and clinically meaningful improvements in motor function scores across SMA patient cohorts.
    → Commercial authorization of a first-in-class adjuvant therapy unlocks addressable market access and commercial product revenue for SRRK.
    Impact
    The FDA granted commercial marketing approval for Isembyld (apitegromab-mstn), marking the first regulatory clearance for a muscle-directed SMA therapy. The treatment is indicated for use in combination with existing SMN upregulators. The approval follows positive Phase 3 SAPPHIRE study readouts showing statistically significant and clinically meaningful improvements in motor function scores across SMA patient cohorts.
    Affected
    SRRK
    Transmission
    Commercial authorization of a first-in-class adjuvant therapy unlocks addressable market access and commercial product revenue for SRRK.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    SRRKcommercial product revenue inflection from FDA approvalUp1-5dFDA approved Isembyld (apitegromab-mstn) for spinal muscular atrophy.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month